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Background: Anemia management protocols in hemodialysis (HD) units differ conspicuously regarding optimal
intravenous (IV) iron dosing; consequently, patients receive markedly different cumulative exposures to IV iron and
erythropoiesis-stimulating agents (ESAs). Complementary to IV iron safety studies, our goal was to gain insight into
optimal IV iron dosing by estimating the effects of IV iron doses on Hgb, TSAT, ferritin, and ESA dose in common
clinical practice.
Methods: 9,471 HD patients (11 countries, 2009-2011) in the DOPPS, a prospective cohort study, were analyzed.
Associations of IV iron dose (3-month average, categorized as 0, <300, ≥300 mg/month) with 3-month change in
Hgb, TSAT, ferritin, and ESA dose were evaluated using adjusted GEE models.
Results: Relative change: Monotonically positive associations between IV iron dose and Hgb, TSAT, and ferritin
change, and inverse associations with ESA dose change, were observed across multiple strata of prior Hgb, TSAT,
and ferritin levels. Absolute change: TSAT, ferritin, and ESA dose changes were nearest zero with IV iron <300 mg/
month, rather than 0 mg/month or ≥300 mg/month by maintenance or replacement dosing. Findings were robust
to numerous sensitivity analyses.
Conclusions: Though residual confounding cannot be ruled out in this observational study, findings suggest that
IV iron dosing <300 mg/month, as commonly seen with maintenance dosing of 100-200 mg/month, may be a
more effective approach to support Hgb than the higher IV iron doses (300-400 mg/month) often given in many
European and North American hemodialysis clinics. Alongside studies supporting the safety of IV iron in 100-200
mg/month dose range, these findings help guide the rational dosing of IV iron in anemia management protocols
for everyday hemodialysis practice.
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Anemia due to deficient renal erythropoietin production
is nearly universal among hemodialysis (HD) patients.
Treatment with erythropoiesis-stimulating agents (ESAs)
and intravenous (IV) iron has been the cornerstone of
anemia management for over two decades, and it is well
established that IV iron is vital to support hemoglobin
(Hgb) levels and optimize ESA dosing [1–5].
Despite this, the optimal IV iron management prac-
tice to support ESA therapy remains uncertain. First,
there may be safety considerations that should limit the
amount of IV iron given to patients. While pre-clinical
and small clinical studies have indicated that IV iron
may lead to oxidative stress, inflammation, risk of
infection, and tissue iron overload, large observational
studies have reported incongruent associations with
clinical outcomes [6–21]. A 2014 KDIGO Controversies
Conference on iron management in CKD focused
nearly exclusively on the safety of IV iron [22]. Simi-
larly, an ongoing multicenter clinical trial in the UK
will compare the safety of a high-dose versus a low-
dose IV iron regimen [23].
These questions about the safety of IV iron underlie
the imperative to understand the most effective IV iron
management strategies, i.e., to give the ‘right amount’ of
IV iron to support ESA use and target hemoglobin levels
in everyday practice. Data from small clinical trials show
that Hgb responsiveness to ESA dosing improves with
IV iron dosing that achieves higher levels of iron mea-
sures, e.g., transferrin saturation (TSAT) levels of 30%-
35% [24–30]. However, ‘real world’ data on the best IV
iron dosing strategies to support anemia management
are lacking, with a dearth of publications comparing the
effectiveness of different IV iron dosing approaches.
Uncertainty regarding optimally effective IV iron
management strategies, including IV iron dosing and
TSAT and ferritin targets, is reflected in clinical prac-
tice recommendations that differ conspicuously: e.g.,
the KDIGO anemia guideline in 2012 and the ERBP
and KDOQI responses to this guideline in 2013 [31–35].
In this context, it is not surprising that previous DOPPS
publications have demonstrated that protocols for anemia
management and IV iron dosing are widely variable within
and across countries [36–39]. As a consequence, patients
receive markedly different cumulative exposures to IV
iron and ESAs, and ferritin levels are now much higher in
the US than in other countries, as are TSAT levels to a
lesser extent [40–42].
The primary goal of this study was to help to determine
if there is an IV iron management strategy that would
optimize the effect of IV iron dosing on Hgb levels and,
secondarily, on TSAT, ferritin, and ESA dose in common
clinical practice. In the context of unresolved safety ques-
tions, we hope to inform optimal IV iron managementpractices to support Hgb levels while limiting unnecessary
or excessive use of ESAs and IV iron.
Methods
DOPPS Participants and Data
The Dialysis Outcomes and Practice Patterns Study
(DOPPS) is an international prospective cohort study
of hemodialysis patients ≥ 18 years of age. Patients
are enrolled randomly from national samples of dialy-
sis facilities in each participating country [43, 44].
Demographic data, comorbid conditions, laboratory
values, and medications were abstracted from patient
records at study enrollment. Laboratory measures and
renal medications were updated monthly. Study ap-
proval was obtained by a central institutional review
board, and as required by national and local ethics
committees. Written, informed consent was obtained
from all participants.
Analysis sample
All patients (n=15,019) from DOPPS phase 4 (2009-2011)
in Europe-A/NZ (Belgium, France, Germany, Italy, Spain,
Sweden, and the United Kingdom, plus Australia and New
Zealand), and North America (Canada, United States)
were eligible for the analysis sample. Patients from Japan
were excluded due to much lower levels of IV iron pre-
scriptions. Additional file 1: Figure S1 diagrams a selection
of the analysis sample. Patients were required to receive
dialysis for at least 4 consecutive months (labeled as
months 0 to 3), have TSAT and ferritin values reported at
months 0 and 3, have IV iron dosing information for at
least 2 of 3 months between the month 0 and 3 lab values,
and survive for at least 2 months after month 3, for an
analysis sample of 9,471 patients. For patients with mul-
tiple suitable 4-month periods, the first period was used.
The 3-month interval length was selected because most
facilities measure TSAT and ferritin lab values at least
quarterly.
Analytic approach
Monthly IV iron and ESA doses were estimated based
on the prescription at the end of each month. Patients
not prescribed IV iron or ESA were considered to have
a 0 dose for the month. ESA doses were standardized
to IV epoetin equivalent units, using a factor of 200 to
convert darbepoetin alfa and a factor of 1.15 to convert
subcutaneous epoetin [34]. The primary exposure was
the average monthly IV iron dose over months 0 to 3
(Additional file 2: Figure S2). The outcomes were
changes from month 0 to month 3 in Hgb, TSAT,
ferritin, ESA dose, and CRP (denoted with Δ and sub-
scripts 3-0 , e.g., ΔHgb3-0).
Primary analyses were modeled separately for 14 differ-
ent strata: 4 categories of Hgb0, 5 categories of TSAT0,
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equation (GEE) model was used to estimate the expected
change in outcomes separately for each stratum condition
and reported for each IV iron category (holding all adjust-
ment variables constant). Trends across IV iron categories
in each stratum were also tested with p-values reported.
Each model was adjusted for demographics (age, sex,
black race), body mass index, time on dialysis, catheter
use, region (North America, Europe-A/NZ), 13 summary
comorbid conditions, laboratory values at month 0 (Hgb,
ferritin, TSAT, albumin, creatinine, white blood cell
count), and ESA dose averaged over months 0 to 3 (unless
included in the outcome or strata). Hgb, TSAT, and fer-
ritin were categorized according to common clinical cut
points. For the primary analysis, IV iron categories (no IV
iron [0 dose], 1 to <300, and ≥300 mg/month) were based
on a previous DOPPS publication demonstrating no eleva-
tion in mortality at <300 mg/month [6]. Additional ana-
lyses dichotomized the ≥300 mg/month IV iron dose
category according to replacement dosing (defined as
≥500 mg during any of the 3 months) or maintenance
dosing (300-499 mg per month in all 3 months). Multiple
sensitivity analyses were performed.
There were few missing values (<2% for the majority
of covariates, < 6% for all). Ninety-eight percent of the
sample had 3 months of IV iron dosing information, and
2% had 2 months. For missing data, we used the Sequen-
tial Regression Multiple Imputation Method by IVEware
[45], and analyzed using the MIAnalyze procedure in
SAS/STAT® 9.3. Adjustment variables, but not outcome
variables, were imputed. Analyses used SAS version 9.3
(SAS institute, Cary, NC).
Results
Distribution of IV iron doses
Thirty percent of patients received no IV iron over
three months; 40% received (on average) <300 mg/
month, and 30% received ≥300 mg/month (Additional
file 3: Figure S3). IV iron dose distributions in North
America (58% of sample) were similar to Europe-A/NZ
(42% of sample). The most common doses were 100
mg/month in the <300 mg/month group and 400 mg/
month in the ≥300mg/month group. Seventy-three
percent of patients remained in the same IV iron dose
category from 1 to 3 months, and 66% with one year of
follow-up remained in the same IV iron dose category
from 3 to 12 months (Additional file 4: Table S1).
Patient characteristics by IV iron dose categories (Table 1)
Clinically meaningful differences in age, sex, and most
comorbidities were not observed by IV iron dose cat-
egory. Patients receiving higher doses of IV iron were
more likely to receive dialysis via a central venous
catheter.Change in Hgb (Fig. 1)
Relative change: A positive trend (p<0.05) between the
three average monthly IV iron dose categories and
ΔHgb3-0 was observed in all but one of the 14 total
Hgb0, TSAT0, and ferritin0 strata. For the 14 strata, the
median (range) difference in ΔHgb3-0 was 0.18 (0.10 to
0.41) g/dL for IV iron <300 mg/month compared to no
IV iron, and 0.13 (-0.07 to 0.40) g/dL for IV iron ≥300
mg/month compared to <300 mg/month. Absolute
change: Across Hgb0 strata, the absolute ΔHgb3-0
showed regression to the mean (generally consistent
with treatment to target Hgb); namely Hgb increased for
patients with Hgb0 <11 g/dL in all IV iron dose categor-
ies, and decreased for patients with Hgb0 ≥12 g/dL in all
IV iron dose categories. By contrast, in all but two
TSAT0 and ferritin0 strata the absolute ΔHgb3-0 was
negative when the mean monthly IV iron dose was 0.
Across TSAT0 and ferritin0 strata, the absolute ΔHgb3-0
was near zero or slightly positive for IV iron <300 mg/
month and ≥300 mg/month.
Change in ESA dose (Fig. 2)
Relative change: An inverse relationship (p<0.05) be-
tween the three average monthly IV iron dose categories
and ΔESA dose3-0 was observed in all but three of 14
total Hgb0, TSAT0, and ferritin0 strata. Absolute
change: The estimates for absolute ΔESA dose3-0 were
positive for IV iron 0 mg/month in 13 of the 14 total
Hgb0, TSAT0, and ferritin0 strata, and were negative for
IV iron ≥300 mg/month in all 14 Hgb0, TSAT0, and fer-
ritin0 strata. Estimates for absolute ΔESA dose3-0 were
generally nearer to zero with IV iron <300 mg/month
than with either 0 or ≥300 mg/month. The differences
in absolute ΔESA dose3-0 across the three IV iron dose
groups were greater in the low compared to high Hgb0
and TSAT0 strata. No such pattern was evident across
ferritin0 strata.
Changes in TSAT (Fig. 3) and ferritin (Fig. 4)
Relative change: Positive trends (p<0.05) between the
three average monthly IV iron dose categories and both
ΔTSAT3-0 and Δferritin 3-0 were observed in all 14 total
Hgb0, TSAT0, and ferritin0 strata. These associations were
directionally similar to those for change in Hgb (Fig. 1).
Maintenance versus replacement dosing patterns in the
≥300 mg/month category (Additional file 5: Figure S4)
Among patients in the ≥300 mg/month category, the asso-
ciations of IV iron dosing with ΔHgb3-0 were comparable
across Hgb0 strata for the replacement versus mainten-
ance IV iron dosing subgroups. In general, maintenance
dosing had a weaker (less positive) effect on ΔTSAT3-0
and a stronger (more positive) effect on Δferritin 3-0 than
replacement dosing.
Table 1 Baseline characteristics by monthly IV iron dose category
IV Iron (mg/mo, average over 3 months)a p valueb
0 <300 ≥300
Study sample
Patients, N 2800 3749 2922
Patients, % 30 40 30
Region, row %
North America 29 41 30 0.94
Europe and Australia/New Zealand 30 37 32 0.94
Demographics
Age, years 64.0 64.0 63.5 0.06
BMI, kg/m2 27.0 27.5 27.9 <.01
Male, % 57 58 58 0.47
Black, within US only, % 33 31 29 <.01
Duration on dialysis, years 4.7 4.1 3.0 <.01
Catheter, % 25 29 39 <.01
Comorbidities, %:
Diabetes 47 51 54 <.01
Hypertension 85 83 84 0.53
Coronary Heart Disease 37 36 35 0.16
Cerebrovascular Disease 13 14 14 0.77
Congestive Heart Failure 30 30 28 0.80
Peripheral Vascular Disease 26 25 25 0.22
Other Cardiovascular 25 25 26 0.59
Cancer (non-skin) 13 11 13 0.87
GI Bleed (within 12 months) 4 4 5 0.23
Lung Disease 13 13 13 0.77
Neurologic Disease 10 9 9 0.19
Psychiatric Disorder 17 16 15 0.20
Recurrent Cellulitis or Gangrene 9 10 9 0.89
Laboratory Values (at month 0)
Albumin, g/dL 3.79 3.77 3.68 <.01
Creatinine, mg/dL 8.3 8.0 7.5 <.01
White Blood Cells, x 103/uL 7.0 7.0 7.2 <.01
TSAT, % 31.5 29.0 23.8 <.01
Ferritin, ng/mL 687 538 441 <.01
Hemoglobin, g/dL 11.6 11.5 11.2 <.01
CRP, mg/Lc 12.7 11.9 15.8 0.35
Medication Doses (3-month average)
IV Iron, mg/month 0 170 523
ESA, IV epoetin equivalent units/week 10759 11426 16101 <.01
aValues in table are sample mean unless noted otherwise
bp value for trend within row (across three iron dose categories), adjusted for region and accounting for facility clustering, using logistic model for dichotomous
and linear mixed model for continuous measures
cRestricted to facilities measuring CRP in at least 50% of their patients (all North American facilities excluded)
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Fig. 1 Adjusted change in Hemoglobin, from before to after IV iron dosing. Each stratum represents a separate model (14 total per figure)
adjusted for age, sex, black race, time on dialysis, catheter use, BMI, region (Europe-ANZ, North America), 13 comorbid conditions, and the
following measures at month 0: Hgb, white blood cell count; serum albumin, creatinine, ferritin, TSAT; and 3-month ESA dose (unless included
in the outcome or strata). The vertical bars indicate 95% confidence intervals. Total sample size was 9,471
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The associations of IV iron dose on outcomes were
evaluated in additional subgroups such as strata of
Hgb0-by-TSAT0, Hgb0-by-ESA dose, TSAT0-by-ESA
dose (Additional file 6: Figure S5), iron dose over 3
months prior to month 0, and geographic region. For
all categories with adequate sample size, the observed
associations with IV iron dose were consistent with
Figs. 1, 3, and 4. Exclusion of incident patients (<90
days on dialysis) had no material impact on results.
Consideration of other functional forms for IV iron
dose, including as a categorical variable with differentFig. 2 Adjusted change in ESA dose, from before to after IV iron dosing. E
for age, sex, black race, time on dialysis, catheter use, BMI, region (Europe-A
measures at month 0: Hgb, white blood cell count; serum albumin, creatin
outcome or strata). The vertical bars indicate 95% confidence intervals. Tota
“% of patients” adds up to 90%cut points or a continuous variable, yielded results con-
sistent with the primary analysis. Restricting the IV iron
dose period to 1 month demonstrated that the 1-month
effect on Hgb, TSAT, and ferritin was directionally
unchanged from, though quantitatively lower than, the
3-month effect (Additional file 7: Figure S6). Corrob-
orative results were observed when lagging the out-
come by one month (i.e., to month 4), when evaluating
outcomes over 1 month of IV iron dosing, rather than
3 months, and when stratifying 1 or 3 month IV iron
dose by prior 3-month iron dose, in effect providing
estimates of the effect of a 4- to 6-month IV iron dose.ach stratum represents a separate model (14 total per figure) adjusted
NZ, North America), 13 comorbid conditions, and the following
ine, ferritin, TSAT; and 3-month ESA dose (unless included in the
l sample size was 9,471, with 10% missing outcome variable hence
Fig. 3 Adjusted change in TSAT, from before to after IV iron dosing. Each stratum represents a separate model (14 total per figure) adjusted for
age, sex, black race, time on dialysis, catheter use, BMI, region (Europe-ANZ, North America), 13 comorbid conditions, and the following measures
at month 0: Hgb, white blood cell count; serum albumin, creatinine, ferritin, TSAT; and 3-month ESA dose (unless included in the outcome or
strata). The vertical bars indicate 95% confidence intervals. Total sample size was 9,471
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Strata of CRP0 (<3, 3-<10, and 10+ mg/dL), an inflamma-
tory measure obtained commonly in European dialysis
units, were evaluated. No directional associations were
seen between average monthly IV iron dose and 3-month
change in C-reactive protein, in contrast with the clear
patterns of ‘dose response’ observed for the anemia-
related outcomes.
Discussion
Our findings, from a multinational observational study
of practice patterns in national samples of hemodialysis
centers, provide support for the effectiveness of IV ironFig. 4 Adjusted change in Ferritin, from before to after IV iron dosing. Eac
for age, sex, black race, time on dialysis, catheter use, BMI, region (Europe-A
measures at month 0: Hgb, white blood cell count; serum albumin, creatin
outcome or strata). The vertical bars indicate 95% confidence intervals. Totadosing to raise or sustain Hgb across a wide range of
starting Hgb, TSAT, and ferritin values in everyday prac-
tice. Specifically, the results support the possibility that
IV iron dosing of less than 300 mg/month, as commonly
used for maintenance IV iron dosing at 50 mg per week
or 50-100 mg every other week (the dominant dose
range for this category was 100-200 mg/month) may be
the most effective strategy to support Hgb while keeping
TSAT and ferritin levels stable and limiting ESA dose.
Higher IV iron doses were associated with lower doses
of ESA, but at a price of a rise in ferritin (especially with
maintenance dosing) and/or TSAT (especially with re-
placement dosing). Along with studies supporting theh stratum represents a separate model (14 total per figure) adjusted
NZ, North America), 13 comorbid conditions, and the following
ine, ferritin, TSAT; and 3-month ESA dose (unless included in the
l sample size was 9,471
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these results provide greater clarity to help guide the ra-
tional use of IV iron in common clinical practice across
a diverse range of dialysis centers and patients, and
across diverse countries.
A motivation for our analysis was the paucity of data
providing practical guidance for the comparative effect-
iveness of different IV iron doses to optimize Hgb out-
comes and ESA responsiveness in dialysis patients,
which could help providers to limit administration of
higher doses than necessary given uncertainty about
clinical risk. Among HD patients with absolute or func-
tional iron deficiency, the effectiveness of IV iron to
raise Hgb levels is established [2, 31–33]. For most HD
patients, who have neither absolute nor functional iron
deficiency, small clinical studies consistently have shown
that optimizing IV iron dosing supports Hgb levels while
decreasing ESA dose requirements [22–30]. However, no
interventional trials or adequately controlled large obser-
vational studies have sufficiently evaluated the effective-
ness of different IV iron dosing strategies to support Hgb
responsiveness to ESA dosing in broader dialysis practice.
Absent clear evidence or consensus guidelines, anemia
management protocols are highly diverse, and patients re-
ceive markedly different cumulative exposures to IV iron
and ESAs [31–38].
To help address this evidence gap, our analysis corrobo-
rates the positive dose response (relative change) between
IV iron and Hgb, TSAT, and ferritin levels, well known
from smaller studies, in a large database reflective of
routine clinical care in diverse settings internationally.
This work also provides estimates of the magnitude of the
effect of IV iron on 3-month change in Hgb in routine
clinical practice, demonstrating a median difference of
0.18 g/dL for IV iron doses of <300 mg/month versus 0,
and of 0.13 g/dL for IV iron doses of ≥300 versus <300
mg/month, varying modestly across Hgb0, TSAT0, or fer-
ritin0 strata.
Based on our Medical Director Survey data (not
shown) specifying target ranges for Hgb, TSAT, and
ferritin levels, the majority of patients in this analysis
had values of these measures that were at or near tar-
get range. For such patients, an important goal of
anemia management is to maintain Hgb at stable
levels (i.e., absolute change of zero), while optimizing
ESA dosing. Deviations have been referred to as Hgb
variability, cycling, or excursions, and have been
associated with adverse clinical outcomes [46–49].
Furthermore, maintaining stable TSAT and ferritin
levels in the target range plausibly has beneficial clin-
ical and cost implications. In our analyses, we note
that Hgb, TSAT, and ferritin levels were most often
unchanged (absolute change = 0) from before to after
IV iron dosing of <300 mg/month. This finding heldacross broad ranges of prior Hgb, TSAT, and ferritin
levels, inclusive of common targets such as Hgb 10-12
g/dL, TSAT 20%-34%, and ferritin 200-799 ng/mL.
The <300 mg/month IV iron dosing category includes
some common maintenance IV iron dosing regimens,
e.g., 50 mg/week or 50-100 mg every other week (Add-
itional file 3: Figure S3). We therefore extrapolate that
this IV iron dosing strategy may be the best means to
maintain stable Hgb, TSAT, and ferritin levels in many
patients.
Among patients receiving IV iron at ≥300 mg/month,
our analysis estimated the effects of high dose mainten-
ance (e.g., 100 mg weekly) versus replacement (e.g.,
500mg or 1000 mg bolus) dosing (Additional file 5:
Figure S4). While the observed effects on Hgb levels
were comparable, both strategies were associated with
increases in TSAT and ferritin levels even among pa-
tients with high prior TSAT (up to 35%) and ferritin
(up to 1200 ng/mL) levels. These observed effects may
indicate administration of unnecessarily high cumula-
tive IV iron doses; for example, maintenance dosing
(which has lesser short-term, but perhaps greater long-
term, effect on raising ferritin levels than replacement
dosing) was associated with an increase in ferritin of an
additional 63 ng/mL for patients with ferritin levels
already at 500-799 ng/mL. These findings provide fur-
ther support for use in common practice of IV iron
dosing at <300 mg/month, compared to ≥300 mg/
month whether by maintenance or replacement dosing.
Relative decreases in 3-month ESA dose were consist-
ently seen for IV iron dose <300 mg/month compared
to no IV iron, especially at low Hgb0 and TSAT0 levels.
While IV iron ≥300 mg/month was associated with even
larger relative decreases in 3-month ESA dose, the abso-
lute change in ESA dose was generally closest to 0 fol-
lowing IV iron dosing of <300 mg/month. This finding
supports the possibility that IV iron dosing at <300 mg/
month may, on average, limit the need for ESA dosing
adjustments, a desirable goal in everyday dialysis prac-
tice. Especially for patients with low Hgb0 (<11 g/dL) or
low TSAT0 (<20%) levels, the large increase in Hgb level
and large decline in ESA dose following IV iron dosing
emphasize the importance of sufficient IV iron dosing in
such patients to limit unnecessarily high ESA dose.
Our analysis evaluated effectiveness rather than safety
outcomes, but our conclusion that IV iron dosing at 100-
200 mg/month (the most common doses in <300mg/
month group) may be optimally effective to support Hgb
levels is notable when placed in the context of existing
literature because, to our knowledge, studies have found
elevation in clinical risk only at higher (e.g., ≥300 mg/
month) IV iron doses [6–14].
Regarding interpretation of our findings, several
caveats merit mention. First, though we evaluated the
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needed to confirm our findings over longer follow-up
intervals. Second, the analysis provides information on
average, but doesn’t provide insight into the most ef-
fective IV iron dosing strategies for all situations in
clinical practice, such as patients with Hgb levels sub-
stantially above or below target or patients who are hy-
poresponsive to ESA therapy. Third, this was a study of
prevalent HD patients, most of whom are not naïve to
anemia treatment; however, prior treatment history
cannot be fully represented in the analysis. Fourth, all
observational studies are subject to biased interpret-
ation due to confounding. However, the associations
seen are directionally consistent with causal rather than
confounded interpretations. Confounding would tend
to bias the effect of IV iron on Hgb to the null, since
patients receiving higher doses of IV iron are more
likely to be ESA resistant than patients receiving lower
dose or no IV iron. Fifth, we were unable to report esti-
mated effects of different IV iron formulations because,
within a geographic region, there was often only one
product in predominant use [38, 40].
Conclusion
Though IV iron use in dialysis units is nearly ubiquitous,
the optimal way to dose and manage iron parameters to
treat anemia is controversial and deserves input from ana-
lyses of actual clinical practice. Our observational findings
from the international DOPPS provide support for the
effectiveness of IV iron dosing to raise or sustain Hgb
levels across a wide range of Hgb, TSAT, and ferritin
values. Further, the findings indicate that IV iron dosing at
<300 (typically 100-200) mg/month, as used for some
maintenance IV iron dosing protocols, may be a more
suitable strategy for average patients to support Hgb,
while keeping TSAT and ferritin levels stable and reducing
or limiting ESA doses, than the higher doses, by either
maintenance or replacement dosing, that are common in
many European and North American dialysis clinics.
Along with studies that support the safety of IV iron in
the same 100-200 mg/month dose range, these findings
can help to inform clinical practice guidelines and anemia
management protocols in everyday hemodialysis practice.
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